A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

Eyetech Pharmaceuticals

Status and phase: Unknown; Phase 4

Conditions: Age-Related Macular Degeneration (AMD)

Treatments: Drug: pegaptanib sodium (Macugen)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00354445

EOP1023

Details and patient eligibility

About

The purpose of this study is to explore the safety and efficacy of Macugen given as maintenance therapy in patients who have had initial success with another AMD treatment. Patients must have 1, but not more than 3 prior treatments for Neovascular AMD.

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subfoveal CNV secondary to AMD
• At least 1 but not more than 3 prior treatments for AMD

Exclusion criteria

• Subfoveal scar or subfoveal atrophy
• Significant media opacities, including cataract, which might interfere with visual acuity

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)